State-of-the-Art Paper
The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction

https://doi.org/10.1016/j.jcin.2009.10.004Get rights and content
Under an Elsevier user license
open archive

Recently, a growing body of clinical data has shown that the first generation of drug-eluting stents (1st-gen DES) implantation could elicit coronary conduit artery vasomotor dysfunction at nonstented reference segments as late as 12 months after implantation compared with that seen with bare-metal stents. The mechanism of this phenomenon is still not fully understood. Pathological studies have implicated delayed arterial healing and poor re-endothelialization after the 1st-gen DES implantation. Given the vast use of DES globally, a thorough understanding of the early and long-term safety of these devices is paramount. Therefore, this article systematically reviews the current clinical, pathophysiological, and histopathological available data regarding 1st-gen DES-associated vascular endothelial dysfunction. Meanwhile, we will also review the newer generation of DES and emerging endothelial-friendly technology.

Key Words

drug-eluting stents
endothelial
vasomotor dysfunction

Abbreviations and Acronyms

Ach
acetylcholine
BES
biolimus-eluting stent(s)
BMS
bare-metal stent(s)
CAD
coronary artery disease
DES
drug-eluting stent(s)
EC
endothelial cell
ED
endothelial dysfunction
EES
everolimus-eluting stent(s)
eNOS
endothelial nitric oxide synthase
EPC
endothelial progenitor cell
ET
endothelin
IC
intracoronary
LST
late stent thrombosis
NO
nitric oxide
NSRS
nonstented reference segment(s)
PES
paclitaxel-eluting stent(s)
SES
sirolimus-eluting stent(s)
SMC
smooth muscle cell
ZES
zotarolimus-eluting stent(s)
1st-gen DES
first-generation drug-eluting stent

Cited by (0)

Dr. Yin is currently affiliated with the 1st Affiliated Hospital of Harbin Medical University (HMU), China.